Patent ID: 11920169
Assignee: SANGAMO THERAPEUTICS, INC.
Field: Biotechnology (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. A dimer comprising first and second fusion molecules, the first fusion molecule comprising a DNA binding domain that binds to a first target site and a first wild-type or engineered cleavage domain and the second fusion molecule comprising a DNA-binding domain that binds to a second target site and a second wild-type or engineered cleavage domain, wherein the first and second cleavage domains dimerize when the DNA-binding domains are bound to the first and second target sites separated by 7 base pairs, wherein the first fusion molecule comprises an amino acid linker between the DNA-binding domain and the first cleavage domain, wherein the linker is selected from the group consisting of:, (SEQ ID NO: 114)

SGERRQSHVL;

 

(SEQ ID NO: 100)

SGAIRCHDEFWF;

 

(SEQ ID NO: 91)

SGALQEPWSI;

 

(SEQ ID NO: 138)

SGFNHSSCDVVY;

 

(SEQ ID NO: 147)

QSGKIASPHVVI;

 

(SEQ ID NO: 154)

SGTPHEVGVYTL;

 

(SEQ ID NO: 254)

MGDEHRKLRLMSQMRLQVD;

 

(SEQ ID NO: 255)

KPRTDRKIFSLRLAN;

 

(SEQ ID NO: 266)

NPLPRNKYPSPYFLH;

 

(SEQ ID NO: 267)

APPAASKSRTWEMRR;

 

(SEQ ID NO: 268)

LNRPKLNTRPHYTSV;

and

 

(SEQ ID NO: 269)

QTRPPRSFCMLAMTG.